Work

Prospective Evaluation of the Utility of the Serum Free Light Chain Assay (FLC), Clonal Ig VL Gene Identification and Troponin I Levels in a Phase II Trial of Risk-Adapted Intravenous Melphalan with Adjuvant Thalidomide and Dexamethasone for Newly Diagnosed Untreated Patients with Systemic AL Amyloidosis